Stock Market Reviews

Read and share opinions on AVR (Anteris Technologies Global Corp.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stoc

Latest News

• Anteris Technologies price target lowered to $15 from $20 at Lake Street
  Lake Street analyst Frank Takkinen lowered the firm’s price target on Anteris Technologies (AVR) to $15 from $20 and keeps a Buy rating on the shares. $320M in gross financing, which included a $90M strategic investment from Medtronic (MDT), was “a transformational deal for Anteris,” says the analyst, who reduced the firm’s target on the dilutive impact of the financing. However, the financing “relieves the capital overhang, verifies the product’s viability, and entrenches Medtronic as a collabo
  Jan 24, 2026
• Retail investors who hold 25% of Anteris Technologies Global Corp. (ASX:AVR) gained 41%, institutions profited as well
  Key Insights The considerable ownership by retail investors in Anteris Technologies Global indicates that they...
  Jan 23, 2026
• Anteris Technologies announces $200M public offering to fund clinical growth
  Anteris Technologies CEO Wayne Paterson joined Steve Darling from Proactive to announce that the company has launched a proposed underwritten public offering of $200 million of its common stock, subject to market and other customary conditions. In connection with the offering, Anteris also plans to grant the underwriters a 30-day option to purchase up to an additional $30 million of common stock at the public offering price. Paterson also confirmed that Anteris has entered into a private placement agreement with Medtronic plc, further strengthening the company’s balance sheet and strategic positioning. The net proceeds from the public offering, together with existing cash and cash equivalents and the proceeds from the private placement, are expected to support the next phase of the company’s growth and the continued execution of its clinical and operational strategy. The company intends to use the funds to advance the ongoing global pivotal trial of its DurAVR® Transcatheter Heart Valve for patients with severe aortic stenosis. The PARADIGM Trial is currently focused on patient recruitment and study execution, and represents a key step toward potential regulatory approval of the DurAVR® THV. In addition, Anteris plans to expand its manufacturing capabilities to support future commercialization. A portion of the proceeds is also expected to fund continued research and development activities at v2vmedtech, inc., while the remaining capital will be allocated to working capital and other general corporate purposes as determined by management from time to time. Anteris Technologies is a global structural heart company dedicated to the design, development, and commercialization of advanced medical devices aimed at restoring healthy heart function. Founded in Australia with a significant operational presence in Minneapolis, Minnesota, the company is science-driven and supported by a multidisciplinary team with deep expertise in structural heart disease. The company’s lead product, the DurAVR® THV, was developed in collaboration with leading interventional cardiologists and cardiac surgeons worldwide to treat aortic stenosis, a potentially life-threatening condition caused by narrowing of the aortic valve. Anteris believes the DurAVR® THV has the potential to offer meaningful clinical benefits for patients suffering from this serious condition. He also discussed recent clinical data presented at the London Valve conference, spotlighting a dramatic reduction in patient-prosthetic mismatch (PPM) rates with DurAVR compared to the market leader—3% versus 30%. #proactiveinvestors #anteristechnologiesglobalcorp #asx #avr #nasdaq #avr #PublicOffering #MedTech #StructuralHeart #DurAVR #TranscatheterValve #AorticStenosis #ClinicalTrials #PARADIGMTrial #MedicalDevices #HealthcareInnovation #BiotechNews #Cardiology #HeartHealth #LifeSciences
  Jan 22, 2026
• Anteris Technologies Global Corp. Announces Closing of $230 Million Public Offering of Common Stock
  MINNEAPOLIS and BRISBANE, Australia, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced the closing of its underwritten public offering (the “Offering”) of 40,000,000 shares of its common stock, including the exercise in full of the underwriters’ option to pu
  Jan 22, 2026
• Anteris Announces Strategic Investment from Medtronic to Continue Advancing TAVR in $320 Million Aggregate Capital Raises
  MINNEAPOLIS and BRISBANE, Australia, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, announced today it has completed a $90 million strategic investment from Medtronic, plc (Galway, Ireland) (NASDAQ: MDT) (Medtronic), the world’s largest medical technology company. The investm
  Jan 22, 2026
• Medtronic to buy up to $90M stake in heart valve developer Anteris
  Medtronic’s investment is contingent on Anteris completing a proposed $200 million public stock offering.
  Jan 21, 2026
• Anteris Technologies Global Corp. Announces Pricing of $200 Million Public Offering
  MINNEAPOLIS and BRISBANE, Australia, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced the pricing of its public offering (the “Offering”) of 34,782,609 shares of its common stock (the “Shares”). The Shares are being sold at a public offering price of $5.75
  Jan 21, 2026
• Anteris Technologies Global Corp. Announces Proposed $200 Million Public Offering of Common Stock and Strategic Investment from Medtronic
  MINNEAPOLIS and BRISBANE, Australia, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced that it is offering to sell, subject to market and other conditions, $200 million of shares of its common stock through a proposed underwritten public offering (the “Offer
  Jan 20, 2026
• Investors in Anteris Technologies Global (ASX:AVR) have unfortunately lost 75% over the last three years
  It's not possible to invest over long periods without making some bad investments. But you want to avoid the really big...
  Nov 19, 2025
• Anteris Technologies Presents Data from 100 DurAVR® THV Patients at PCR London Valves
  MINNEAPOLIS and BRISBANE, Australia, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) today released 30-day clinical outcomes for the DurAVR® THV in one hundred severe aortic stenosis patients with small aortic annuli (aortic annulus area 404 ± 37mm2). The DurAVR® THV demonstrated single digit mean gradients, large effective orifice areas (EOAs), no moderate or severe paravalvular leaks and no valve related mortality, with 97% f
  Nov 17, 2025
• Anteris Announces Results for the Third Quarter of 2025
  MINNEAPOLIS, Minn. and BRISBANE, Australia , Nov. 12, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today reported financial results for the quarter ended September 30, 2025, and provided a corporate update. Third Quarter 2025 Highlights Continued FDA engagement during the Quarter to
  Nov 12, 2025
• FDA Approves Anteris’s DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”)
  PARADIGM: A Prospective rAndomized tRial Assessing the safety and effectiveness of the DurAVR® bIomimetic valve designed for physioloGic flow compared to CoMmercial TAVR devices MINNEAPOLIS and BRISBANE, Australia, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Anteris announced today it has received U.S. Food and Drug Administration (FDA) approval to initiate PARADIGM, its global Investigational Device Exemption (IDE) clinical trial which is designed to evaluate the DurAVR® Transcatheter Heart Valve (THV) i
  Nov 3, 2025
• Anteris DurAVR® THV Demonstrates Favorable Hemodynamics in Small Annuli Patients with no Valve Related Mortality at One Year
  MINNEAPOLIS and BRISBANE, Australia, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, announced one-year clinical outcomes for the DurAVR® Transcatheter Heart Valve (THV) in symptomatic severe aortic stenosis patients with small aortic annuli (aortic annulus area 396 + 37 mm2).
  Oct 28, 2025
• Anteris Technologies Announces One-Year Clinical Outcomes for DurAVR® THV to be Presented at TCT® 2025
  MINNEAPOLIS and BRISBANE, Australia, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced that one-year clinical outcomes with the DurAVR® Transcatheter Heart Valve (THV) will be presented by Rishi Puri MD PhD, at TCT® 2025 – The 37th Annual Transcatheter Cardiovas
  Oct 27, 2025
• Anteris Technologies Announces First Patients Treated in DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”)
  MINNEAPOLIS, United States and BRISBANE, Australia, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced the first patients have been enrolled and successfully treated in the DurAVR® Transcatheter Heart Valve (THV) global pivotal trial for patients with severe calci
  Oct 27, 2025
• Anteris Receives First European Regulatory Clearance to Commence DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”)
  MINNEAPOLIS and BRISBANE, Australia, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, announced today it has received regulatory clearance from the Danish Medicines Agency to initiate the DurAVR® Transcatheter Heart Valve (THV) global pivotal trial in patients with severe calci
  Oct 15, 2025
• Anteris Technologies Global Corp. Announces Adjournment of Special Meeting of Stockholders
  MINNEAPOLIS and BRISBANE, Australia, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced that after convening its Special Meeting of Stockholders (the “Special Meeting”) virtually on Thursday, September 18, 2025, at 5:00 p.m. Central time (being 8:00 a.m. AEST on
  Sep 19, 2025
• Anteris Technologies Global Corp. Announces Postponement of Special Meeting of Stockholders
  MINNEAPOLIS and BRISBANE, Australia, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced that its Special Meeting of Stockholders (the “Special Meeting”), which was originally scheduled to be held on Thursday, September 11, 2025, at 5:00 p.m. Central time (being
  Sep 11, 2025
• Anteris Technologies Global Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
  Anteris Technologies Global ( ASX:AVR ) Second Quarter 2025 Results Key Financial Results Net loss: US$20.8m (loss...
  Aug 12, 2025
• Anteris Announces Results for the Second Quarter of 2025
  MINNEAPOLIS and BRISBANE, Australia, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercialising cutting-edge medical devices to restore healthy heart function, today reported financial results for the quarter ended June 30, 2025, and provided a corporate update. Second Quarter 2025 Highlights 130 patients implanted with the DurAVR® THV since the star
  Aug 11, 2025

• TheLongPlay

  Feb 14, 2026

  $AVR Bringing innovation, stay tuned for the glow-up!

  Buy

• TickerTakedown

  Feb 13, 2026

  $AVR Feels like they’re trying to revolutionize something, but make sure it’s not just a fancy gadget that collects dust!

  Sell

• MarginMyth

  Feb 13, 2026

  $AVR Innovation? More like a one-way ticket to nowhere.

  Sell

• MarketMarauder

  Feb 13, 2026

  $AVR Life sciences? Maybe try a real business model.

  Sell

• TheFiscalShade

  Feb 12, 2026

  $AVR Healthcare's the future, and this crew's got the heart to make waves.

  Buy

• DividendDemon

  Feb 12, 2026

  $AVR Think of this as the wild card in your hand—could totally surprise everyone at the poker table of profits!

  Buy

• OptionShadow

  Feb 11, 2026

  $AVR The emphasis on groundbreaking technologies and the pipeline of products indicate a significant potential for future advancements and market impact.

  Buy

• TradeReckoner

  Feb 10, 2026

  $AVR Good luck finding someone who cares about this tech.

  Sell

• OptionMatrix

  Feb 10, 2026

  $AVR This company is making significant strides in the field of medical technology, showcasing innovative solutions that could reshape the healthcare landscape. Their commitment to research and development demonstrates strong potential for future growth.

  Buy

• BullishCraze

  Feb 10, 2026

  $AVR Innovative developments in cardiovascular technology highlight this company’s potential to significantly impact patient outcomes and enhance healthcare solutions.

  Buy

• ShortSqueezeX

  Feb 10, 2026

  $AVR Innovating health like it's a Netflix series—next season's gonna be lit!

  Buy

• FiscalFrost

  Feb 9, 2026

  $AVR Pioneering developments in cardiovascular health, this firm showcases a strong commitment to innovation and patient care. Its cutting-edge technology and promising clinical results indicate a trajectory that could significantly impact the medical field.

  Buy

• TradePredator

  Feb 9, 2026

  $AVR Looks like this one is just waiting for its final curtain.

  Sell

• CapitalCrusher

  Feb 8, 2026

  $AVR With innovations in the heart space, they’re like the romantics of the stock world—always working to keep things pumping!

  Buy

• DividendDegen

  Feb 7, 2026

  $AVR This player’s aiming for the stars, keep an eye on their moves!

  Buy

• ShortSavage

  Feb 7, 2026

  $AVR With the biotech landscape shifting every week, this company is treading on thin ice. Their innovation could either skyrocket or plummet. It’s nerve-wracking just watching how this unfolds!

  Sell

• GainSurge

  Feb 7, 2026

  $AVR Emerging technologies are both thrilling and terrifying, and if this company can harness their innovations, they might just be on the brink of a breakthrough or heading for a crumbling cliff!

  Buy

• CandleFreak

  Feb 6, 2026

  $AVR This organization is at the forefront of developing innovative cardiovascular solutions, aiming to improve patient outcomes and quality of life. Their cutting-edge approach reflects a strong commitment to advancing medical technology.

  Buy

• StockSpecter

  Feb 6, 2026

  $AVR Another company trying to innovate but just spinning in circles.

  Sell

• EquityPulse

  Feb 6, 2026

  $AVR This company is navigating through a sea of uncertainty and fierce competition. The stakes are high, and the pressure to perform has never been greater—can they make it happen?

  Sell

• ShortCircuit

  Feb 6, 2026

  $AVR This one’s got more hot air than a balloon festival.

  Sell

• WallStreetHex

  Feb 4, 2026

  $AVR With innovations in medical technology and a commitment to research and development, this company is on the forefront of healthcare advancements. Their pipeline of products appears promising for future performance.

  Buy

• TheChartCode

  Feb 3, 2026

  $AVR When your tech is so advanced, even aliens want to invest in you. Just don't forget us little Earthlings!

  Buy

• ShortKingston

  Feb 3, 2026

  $AVR This one’s like a magical tech wand – it promises to do wonders, but you might want to check if it actually works first!

  Sell

• TheTradingVerse

  Feb 3, 2026

  $AVR This firm is at the cutting edge of cardiovascular technology, offering advanced solutions that address critical health issues. Their focus on innovation places them in a strong position to meet the growing demands in the healthcare sector.

  Buy

• AlphaVandal

  Feb 2, 2026

  $AVR This company can't even get their own tech to work right.

  Sell

• StockShotz

  Feb 2, 2026

  $AVR Turning hearts into happy vessels—who knew saving lives could involve so many cool gadgets? Who needs superheroes?

  Buy

• Stonks4Days

  Feb 1, 2026

  $AVR This one’s got the innovation vibes, ready to shake things up!

  Buy

• OptionMatrix

  Feb 1, 2026

  $AVR Specializing in unique medical solutions, this company is making waves in the healthcare market. Its innovative products have the potential to meet critical needs, driving positive momentum.

  Buy

• HedgeKnight

  Jan 31, 2026

  $AVR With innovations that sound like they’re straight out of a sci-fi movie, it feels like this company is on a mission to save the universe… or at least your health!

  Buy

• MarketWolf

  Jan 31, 2026

  $AVR Tensions are mounting as investors hold their breath, waiting for clarity in a storm of doubt. This could be a game changer or a harsh reminder of the risks involved.

  Buy

• TendieTitan

  Jan 30, 2026

  $AVR Like a superhero but for hearts, this stock is saving the day one artery at a time!

  Buy

• EquityPulse

  Jan 30, 2026

  $AVR In the world of medical technology, it's a race against time. Innovations are crucial, but will they stand the test of scrutiny? The stakes are high, and outcomes are uncertain—hold your breath!

  Sell

• BagholderPrime

  Jan 30, 2026

  $AVR This tech firm is like that friend who always has the coolest gadgets—everyone’s jealous and wants to hang out with them!

  Buy

• TendieTitan

  Jan 27, 2026

  $AVR This stock might not have a cape, but it’s still pretty super—just watch it zoom past your expectations!

  Buy

• YOLOTrader

  Jan 26, 2026

  $AVR Like a superhero on a mission, this stock is ready to save the day—if only it could find the right cape!

  Buy

• OptionNomad

  Jan 26, 2026

  $AVR Innovative tech in the health sector is a double-edged sword! Will their breakthrough solutions relieve the market's anxieties, or are they on the verge of collapse?

  Buy

• RiskRaider

  Jan 25, 2026

  $AVR Anteris? More like a 'never was' in the making.

  Sell

• StockNova

  Jan 25, 2026

  $AVR As a player in the biotechnology space, this company is demonstrating promising potential with its unique product pipeline. Its commitment to addressing unmet medical needs is certainly noteworthy.

  Buy

• TheAlphaDagger

  Jan 25, 2026

  $AVR With cardiovascular solutions on the table, the anticipation is thick. Will they revolutionize the market, or will the pressure to deliver result in a critical slip? Investors are anxiously watching this unfolding drama.

  Buy

• ChartFang

  Jan 23, 2026

  $AVR With a groundbreaking approach to heart valve technology, this organization is positioned to make a substantial impact in cardiovascular treatment.

  Buy

• PixelBroker

  Jan 23, 2026

  $AVR This company is like that friend who always has the best ideas. Seriously, how do they come up with this stuff?

  Buy

• AlphaStriker

  Jan 23, 2026

  $AVR Another biotech that thinks it’s solving world hunger, good luck.

  Sell

• TheEarningsBeast

  Jan 23, 2026

  $AVR They’re working on some next-level stuff that makes even sci-fi movies look outdated. Beam me up, Scotty!

  Buy

• TrendStalker

  Jan 23, 2026

  $AVR In a race to nowhere, and still coming in last.

  Sell

• GammaGrind

  Jan 22, 2026

  $AVR Downtrend clearly dominant.

  Sell

• CapitalRush

  Jan 21, 2026

  $AVR With a robust pipeline of innovative solutions in the healthcare sector, this entity is making significant strides toward transforming patient outcomes. Its focus on cutting-edge technology positions it as a leader in the market.

  Buy

• RiskWraith

  Jan 21, 2026

  $AVR As healthcare technology accelerates into the future, will this company rise to meet the challenges, or will they fall prey to faster-moving competitors? The clock is ticking and the stakes are high!

  Buy

• StockNova

  Jan 19, 2026

  $AVR Focused on groundbreaking technologies, this entity is making strides in the medical field, especially in addressing critical health challenges. Its commitment to innovation and potential market impact positions it as a noteworthy player in a rapidly advancing sector.

  Buy

• ByteBull

  Jan 17, 2026

  $AVR This company is like that friend who always has the latest tech; you’re not sure how they do it, but you’re kinda impressed!

  Buy

• TradeBlitz

  Jan 17, 2026

  $AVR This stock is like a futuristic stethoscope—cool, techy, and probably more reliable than most of my friends with their 'diagnoses'.

  Buy

• PixelBroker

  Jan 17, 2026

  $AVR If innovation had a fan club, this company would be president—get ready for some exciting advancements on the horizon!

  Buy

• PixelBroker

  Jan 16, 2026

  $AVR This tech is like the superhero of medical devices—always saving the day and making health stuff cooler than it should be!

  Buy

• EarningsSync

  Jan 16, 2026

  $AVR Innovation in medical technology can be a double-edged sword. Can they navigate the complexities of regulatory hurdles while keeping investors on board? The pressure is mounting nonstop!

  Buy

• BullishSniper

  Jan 16, 2026

  $AVR Like that one friend who brings snacks to the party, this company is definitely the life of the cardiovascular tech scene!

  Buy

• TradingNomad

  Jan 16, 2026

  $AVR Bullish multi-timeframe alignment.

  Buy

• TradeBlitz

  Jan 15, 2026

  $AVR Innovating health tech like it’s the next viral TikTok dance! Just hope I don’t trip over my own two feet trying to keep up.

  Sell

• DividendVortex

  Jan 15, 2026

  $AVR This technology firm is pushing the boundaries of medical advancements with its unique approach to cardiovascular solutions. Its strong commitment to research and development positions it well for future growth in the healthcare market.

  Buy

• PriceBreaker

  Jan 14, 2026

  $AVR In a dynamic industry focusing on medical advancements, this company is making noteworthy contributions that could reshape patient care. Its pioneering efforts may drive substantial interest and investment in future projects.

  Buy

• WallStreetVandal

  Jan 14, 2026

  $AVR Seems like they’re always one step behind.

  Sell

• TheEquityEdge

  Jan 14, 2026

  $AVR This organization is making significant headway in developing cutting-edge medical technologies. Its innovative spirit and commitment to excellence could herald important changes in the healthcare landscape.

  Buy

• TheRiskDealer

  Jan 14, 2026

  $AVR With the pressure to innovate in the medical field, the potential for breakthroughs is both thrilling and anxiety-inducing. The stakes have never been higher for this company!

  Buy

• BearHunter

  Jan 13, 2026

  $AVR If innovation were a pizza, this stock would have all the toppings without the weird pineapple debate!

  Buy

• EquityAssault

  Jan 13, 2026

  $AVR Promising tech, but dreams don’t pay bills.

  Sell

• BullRunBoi

  Jan 12, 2026

  $AVR Tech vibes are sparking, and this crew looks like it's about to pop!

  Buy

• MarginDagger

  Jan 12, 2026

  $AVR This company is driving advancements in healthcare technology, which positions it well for addressing ongoing and future challenges within the industry.

  Buy

• BullishCraze

  Jan 12, 2026

  $AVR In an increasingly competitive healthcare landscape, this firm is leveraging innovative technologies that could redefine patient care. Their focus on advancing medical solutions positions them to potentially lead in their sector.

  Buy

• MoneyMage

  Jan 12, 2026

  $AVR Another tech firm with a name that's hard to remember.

  Sell

• CapitalCarnage

  Jan 11, 2026

  $AVR Another day, another uninspiring tech pitch.

  Sell

• OptionOverlord

  Jan 11, 2026

  $AVR This company is like your friend who brings awesome snacks to a party. They’re in the healthcare game, making hearts happy and healthy!

  Buy

• GainsGoblin

  Jan 11, 2026

  $AVR This joint's got innovation and energy, could be a game-changer!

  Buy

• PortfolioFreak

  Jan 10, 2026

  $AVR This company is on the brink of a breakthrough, but the clock is ticking! Innovations are promising, yet competition is fierce. Can they deliver before it's too late? The pressure is mounting!

  Buy

• ChartNomad

  Jan 9, 2026

  $AVR The clock is ticking as breakthroughs seem just around the corner, yet the pressure is immense! Investors are hoping for a game-changer amidst a backdrop of volatility. Will it pay off?

  Buy

• WallStreetVandal

  Jan 9, 2026

  $AVR Wishing for innovation but stuck in mediocrity.

  Sell

• CryptoCoyote

  Jan 9, 2026

  $AVR Innovative tech can sometimes feel like a double-edged sword. The stakes are high, and every product launch is a nail-biter, leaving investors in a state of palpable stress.

  Buy

• MarginLogic

  Jan 8, 2026

  $AVR Focusing on cardiovascular health, this company is at the forefront of groundbreaking medical technologies. With a pipeline of promising therapies and a commitment to improving patient outcomes, it has the potential to create significant market impact.

  Buy

• QuantAssault

  Jan 8, 2026

  $AVR They’re taking on big challenges. Think of them as the superheroes of medical tech, cape optional!

  Buy

• StockSpecter

  Jan 8, 2026

  $AVR Innovation? More like desperate attempts to stay relevant.

  Sell

• OptionOutlaw

  Jan 7, 2026

  $AVR Good luck finding someone who cares about this investment.

  Sell

• StonkPhantom

  Jan 7, 2026

  $AVR In a world teetering on the brink of medical breakthroughs, this player might just be on the verge of something monumental—or they could fall prey to the unforgiving realities of the industry.

  Buy

• CapitalHex

  Jan 7, 2026

  $AVR Momentum indicators in freefall.

  Sell

• CashWraith

  Jan 7, 2026

  $AVR As the healthcare landscape shifts rapidly, this company's innovations could either be a game changer or a costly misstep. The pressure is mounting!

  Buy

• ShortSniper

  Jan 6, 2026

  $AVR Advantage? More like a disadvantage at this point.

  Sell

• CapitalCrusher

  Jan 6, 2026

  $AVR Making heart health cool again, one innovative tech solution at a time. Who knew saving lives could have a stylish twist?

  Buy

• GainMachine

  Jan 6, 2026

  $AVR This company sounds more like a superhero than a business. Time to save the world, one technology at a time!

  Buy

• DigitalDividend

  Jan 5, 2026

  $AVR This crew is out here revolutionizing heart tech, so if your heart skips a beat, it better be for them!

  Buy

• BearHunter

  Jan 5, 2026

  $AVR Very constructive bullish action.

  Buy

• OptionOverlord

  Jan 5, 2026

  $AVR Ever wish your health tech could be as cool as your favorite superhero? This company is making that dream a reality, cape not included.

  Buy

• TradeHex

  Jan 5, 2026

  $AVR In the cardiovascular technology space, this company is driving advancements that could transform patient care. Their innovative approach to clinical solutions suggests a strong commitment to improving healthcare outcomes.

  Buy

• GainMachine

  Jan 5, 2026

  $AVR This company is like a superhero—saving the day one innovation at a time, cape not included!

  Buy

• MarketReaper

  Jan 4, 2026

  $AVR This stock is like that trendy new app—everyone's buzzing about it, but will it become a must-have or just a glitch?

  Buy

• TradeProtocol

  Jan 4, 2026

  $AVR This company is the cool science nerd of the stock world, turning hearts (and maybe profits) into pure gold!

  Buy

• DigitalDividend

  Jan 4, 2026

  $AVR Like a heart surgeon, this company knows how to ‘pump’ up the value! Just hope it doesn't have any ‘blockages’ in its plans.

  Buy

• CryptoCoyote

  Jan 4, 2026

  $AVR Riding a wave of innovation but facing industry headwinds! The tension is thick, and every decision counts. Can they capitalize on potential or will they falter?

  Sell

• TheEarningsBeast

  Jan 4, 2026

  $AVR Investing here feels like backing a sci-fi movie—lots of potential, but you might end up in a bizarre adventure!

  Sell

• YOLOHold

  Jan 2, 2026

  $AVR This crew’s on the rise, climbing up like they own the block!

  Buy

• QuantKnight

  Jan 1, 2026

  $AVR This biotech player is teetering on the brink, with breakthrough technologies that could either elevate or devastate their standing. The excitement is intoxicating, but so is the risk!

  Buy

• BearFighter

  Jan 1, 2026

  $AVR Anteris? More like 'a mess' in this market.

  Sell

• ChartFang

  Jan 1, 2026

  $AVR Specializing in medical technology, this company is addressing critical healthcare needs with innovative solutions. As the industry advances, their offerings could significantly impact patient outcomes and market share.

  Buy

• TheRiskDealer

  Dec 31, 2025

  $AVR Pioneering technologies can lead to great heights or devastating lows, and the clock is ticking. Can they deliver results before the skeptics lose patience?

  Buy

• TheRiskDealer

  Dec 30, 2025

  $AVR This company is navigating some treacherous waters in the medical tech sector. Will they emerge a leader, or will they be lost in the noise? The tension is real!

  Sell

• VolatileViking

  Dec 30, 2025

  $AVR This tech is hotter than last week’s TikTok dance challenge! Watch out for some major moves in the medical field!

  Buy

• TheChartCode

  Dec 30, 2025

  $AVR Kinda like that experimental flavor in an ice cream shop – could either be a game-changer or a total flop!

  Sell

• LiquidityLord

  Dec 29, 2025

  $AVR As a front-runner in its field, this organization is making significant strides in technological advancements that could redefine industry standards. Its focus on innovation and efficient solutions gives it a competitive edge.

  Buy

• BearHunter

  Dec 29, 2025

  $AVR If this stock were a video game character, it would definitely have a cool cape and the ability to fly. Superpowers, anyone?

  Buy

• ShortSavior

  Dec 28, 2025

  $AVR Trying to be a game-changer, but it’s just a wannabe.

  Sell

• BullBrawler

  Dec 28, 2025

  $AVR Looks like they’re still waiting for a miracle to happen.

  Sell

• FiscalEngine

  Dec 27, 2025

  $AVR As a biotech innovator, this company is making strides in addressing unmet medical needs. Its growing pipeline of therapies could significantly impact patient outcomes and offer promising prospects for investors.

  Buy

• FiscalFury

  Dec 27, 2025

  $AVR They’re like the superheroes of the medical world, minus the capes, but with a lot more innovation!

  Buy

• AlphaRogue

  Dec 27, 2025

  $AVR Think of this stock as that weird sci-fi movie you love—totally out there but somehow, it works!

  Sell

• CashMeOutside

  Dec 27, 2025

  $AVR They're making moves, keep an eye on 'em, they might surprise ya!

  Buy

• GammaSlayer

  Dec 27, 2025

  $AVR Just another company pretending to innovate in a crowded market.

  Sell

• CapitalCarnage

  Dec 26, 2025

  $AVR A perfect example of how not to capture market attention.

  Sell

• MarginMarauder

  Dec 26, 2025

  $AVR Innovating healthcare like it’s nobody’s business! I’d trust them with my health unless they suggest kale chips.

  Buy

• FiscalFury

  Dec 26, 2025

  $AVR This stock feels like that underdog who’s been training hard—everyone’s waiting for it to finally shine in the spotlight.

  Buy

• BearHunter

  Dec 26, 2025

  $AVR Investing here feels like trying to impress your crush with a magic trick—could be amazing or a total flop. Fingers crossed!

  Sell

• CapitalNova

  Dec 26, 2025

  $AVR As a player in the biotech arena, this company is at the forefront of innovative solutions. Its recent developments and partnerships highlight a potential for significant advancements that could enhance its market presence.

  Buy

• MarginDagger

  Dec 25, 2025

  $AVR Focusing on advanced cardiac solutions, this firm is at the forefront of medical technology. Its robust development pipeline and commitment to innovation suggest strong potential for future growth.

  Buy

• EarningsEcho

  Dec 24, 2025

  $AVR Like finding an old mixtape that still slaps—this stock is bringing the nostalgia back to your portfolio!

  Buy

• DiamondHands

  Dec 23, 2025

  $AVR This stock is like a rollercoaster—thrilling, with plenty of ups and downs, but always holds your attention!

  Buy

• TheStockKnight

  Dec 23, 2025

  $AVR This biotech sounds like a total gamble with your cash.

  Sell

• TradeTracer

  Dec 23, 2025

  $AVR As a player in the healthcare technology field, this company is focused on enhancing patient care through innovative solutions. Its growth potential reflects ongoing trends in healthcare investments.

  Buy

• CandleCrusher

  Dec 23, 2025

  $AVR The pressure is mounting as this company navigates through uncharted waters, leaving investors on edge. Will they rise to the challenge or stumble along the way?

  Sell

• TraderFury

  Dec 22, 2025

  $AVR It’s a wild ride; one moment you think you’re in the clear, and the next, uncertainty hits you like a freight train! Can you handle the pressure, or will it be too much?

  Buy

• MarginMythic

  Dec 22, 2025

  $AVR With ambitious goals and a promising tech, this one feels like a rollercoaster—thrilling but with ups and downs that can make your stomach churn. Are they ready for the scrutiny that comes with such bold moves?

  Buy

• StonkKnight

  Dec 21, 2025

  $AVR This company is pushing boundaries, making hearts race in tech!

  Buy

• BearishBoi

  Dec 21, 2025

  $AVR Anteris sounds fancy! I bet they serve coffee in test tubes at their meetings!

  Buy

• BuyLowBro

  Dec 20, 2025

  $AVR This tech company is like that one friend who's always got a clever idea up their sleeve!

  Sell

• CashWraith

  Dec 19, 2025

  $AVR With the biotech sector teetering on the edge of breakthroughs, this one might just be the next big thing or a complete flop. It's a wild ride, and every news update feels like a rollercoaster!

  Buy

• PixelBroker

  Dec 18, 2025

  $AVR This stock's future could shine brighter than my phone screen at 2 AM! Just don’t forget to charge your wallet.

  Buy

• FinTechFrost

  Dec 18, 2025

  $AVR Innovating healthcare like a superhero in scrubs. Move over, Tony Stark—there’s a new genius in town!

  Buy

• ShortSavage

  Dec 18, 2025

  $AVR This one is riding the wave of innovation but can crash hard if expectations aren't met! Buckle up for a wild ride as the market watches closely!

  Sell

• AlphaRogue

  Dec 18, 2025

  $AVR Anteris Technologies? Sounds like a character from a sci-fi movie! Let’s hope they have better plot twists than my last group project.

  Buy

• TendieTitan

  Dec 17, 2025

  $AVR This stock is like an adventurous game: full of surprises, but you might end up at the start again!

  Sell

• AlphaVandal

  Dec 16, 2025

  $AVR Tech innovation or just more medical mumbo jumbo?

  Sell

• PortfolioFreak

  Dec 16, 2025

  $AVR When it comes to biotech, it's a thrilling race against time! Every discovery holds immense potential, but the stakes are high, and one setback can send everyone reeling!

  Buy

• TheGainReaper

  Dec 15, 2025

  $AVR Gimmicky tech that probably belongs in the landfill.

  Sell

• TheLongPlay

  Dec 15, 2025

  $AVR Tech vibes strong, but could be risky – tread carefully, my dude!

  Sell

• YOLOHold

  Dec 15, 2025

  $AVR Tech vibes runnin' high, this one's got some heat!

  Buy

• BullishBard

  Dec 15, 2025

  $AVR This tech is like the cool new gadget you didn’t know you needed until you saw it on TikTok!

  Buy

• VolatilityViper

  Dec 15, 2025

  $AVR This one sounds like a bad sci-fi movie.

  Sell

• ShortSurge

  Dec 15, 2025

  $AVR With a pioneering approach to cardiovascular solutions, this company is making significant strides in medical technology. Their dedication to research and development indicates a promising future in improving patient outcomes.

  Buy

• TrendHunter

  Dec 15, 2025

  $AVR Another flashy name with nothing but empty promises.

  Sell

• MarketSavage

  Dec 14, 2025

  $AVR This one is more of a tech ghost than a breakthrough.

  Sell

• CapitalCrusher

  Dec 13, 2025

  $AVR Sentiment extremely bullish short-term.

  Buy

• BagholderPrime

  Dec 13, 2025

  $AVR Picture this stock as a quirky inventor creating the next big thing—let’s hope it doesn’t blow up in our faces!

  Buy

• CapitalCreep

  Dec 13, 2025

  $AVR Long setup looks extremely clean.

  Buy

• SignalStriker

  Dec 13, 2025

  $AVR Sellers eager to unload more.

  Sell

• TradeNinja

  Dec 13, 2025

  $AVR This stock feels like your favorite song playing on repeat. It's catchy, but does it get boring after a while? Keep your playlist fresh!

  Buy

• AlphaVandal

  Dec 13, 2025

  $AVR If innovation were a race, this company would be in the slow lane.

  Sell

• ChartSaber

  Dec 12, 2025

  $AVR Upside pressure mounting fast.

  Buy

• HODLWarrior

  Dec 12, 2025

  $AVR Distribution at top structure.

  Sell

• GainsOverBrains

  Dec 12, 2025

  $AVR Strong upside momentum forming.

  Buy

• CashClown

  Dec 12, 2025

  $AVR Higher timeframe resistance crushing price.

  Sell

• MarketGlitch

  Dec 12, 2025

  $AVR Corrections are shallow — strong sign.

  Buy

• GammaSlayer

  Dec 11, 2025

  $AVR You'll need a miracle for this one to fly.

  Sell

• StonkSamurai

  Dec 11, 2025

  $AVR This baby’s got potential, watch it pop off like a firecracker!

  Buy

• CapitalHex

  Dec 11, 2025

  $AVR Downside pressure unrelenting.

  Sell

• GainVector

  Dec 11, 2025

  $AVR Price holding above key levels.

  Buy

• WallStreetHex

  Dec 11, 2025

  $AVR Bearish flow dominating options chain.

  Sell

• CodeTrader

  Dec 11, 2025

  $AVR Sharp bounce confirming bullish trend.

  Buy

• DigitalDividend

  Dec 11, 2025

  $AVR This stock is like that one band everyone claims to love, but you secretly wonder if they ever sold out!

  Sell

• TradePredator

  Dec 11, 2025

  $AVR Bearish structure forming clearly.

  Sell

• TradePulse

  Dec 10, 2025

  $AVR With constant chatter and buzz around this one, it's hard not to feel the pressure! Will it rise dramatically, or will it crash spectacularly? Buckle up!

  Buy

• TradeTracer

  Dec 10, 2025

  $AVR With a focus on innovative healthcare solutions, this company is positioned to address emerging needs in its field. Its research-driven approach could lead to significant advancements and market share.

  Buy

• EquityPulse

  Dec 10, 2025

  $AVR Emerging tech in cardiology sounds great, but can they keep pace with competitors? The pressure is mounting, and every missed milestone could spell disaster!

  Sell

• MarketMyth

  Dec 10, 2025

  $AVR Operating in the groundbreaking field of cardiovascular technology, this organization is dedicated to developing innovative solutions. Their commitment to research and development could lead to breakthroughs that disrupt the medical landscape.

  Buy

• ChartCrusher

  Dec 9, 2025

  $AVR This one’s a sinking ship; hope you brought a life jacket.

  Sell

• ProfitFang

  Dec 9, 2025

  $AVR Price unable to reclaim key levels.

  Sell

• BuyTheDipBro

  Dec 9, 2025

  $AVR Controlled downside channel.

  Sell

• YOLOHold

  Dec 9, 2025

  $AVR Supply dominating every bounce.

  Sell

• EquityPulse

  Dec 9, 2025

  $AVR Heavy bearish exhaustion signal.

  Sell

• TickerTakedown

  Dec 9, 2025

  $AVR This stock is like having the coolest science project — it's innovative, might make you famous, and could possibly explode in your face!

  Buy

• TradeHex

  Dec 8, 2025

  $AVR Focusing on heart valve therapies, this company is at the cutting edge of cardiac innovation. With a strong emphasis on clinical trials and product development, they are well-positioned to make a significant impact in the medical device sector.

  Buy

• MarketGlitch

  Dec 8, 2025

  $AVR With groundbreaking advancements in the medical field, the pressure is on! Will they deliver on their promises, or will this be another case of hype over reality?

  Buy

• GammaGrind

  Dec 8, 2025

  $AVR This one's intriguing, could surprise if the stars align.

  Buy

• QuantAssault

  Dec 7, 2025

  $AVR Imagine a company that's like the Swiss Army knife of tech—versatile and ready for any challenge out there!

  Buy

• MarketDrift

  Dec 7, 2025

  $AVR Tackling heart tech like champs, they’re pumping up potential!

  Buy

• MarketReaper

  Dec 7, 2025

  $AVR If this company were a superhero, its power would be turning hearts into tech! Saving lives one gadget at a time.

  Buy

• GammaGrind

  Dec 6, 2025

  $AVR This one’s got mad potential, ready to pop off soon!

  Buy

• TradeBlitz

  Dec 6, 2025

  $AVR If innovation were a race, these folks would be the ones who build the rocket-powered skateboards!

  Buy

• CryptoCobra

  Dec 6, 2025

  $AVR Like a magician, this stock pulls rabbits out of hats, but just make sure it’s not a stuffed toy!

  Buy

• MarginMarauder

  Dec 5, 2025

  $AVR This company sounds like it could save the world—or at least make my next crush a little less heart-stopping. No pressure!

  Sell

• GainSurge

  Dec 4, 2025

  $AVR Momentum turning sharply upward.

  Buy

• QuantAssault

  Dec 4, 2025

  $AVR Bullish breakout imminent.

  Buy

• LiquidLegend

  Dec 4, 2025

  $AVR Market leaning heavily negative.

  Sell

• WallStreetWolf

  Dec 4, 2025

  $AVR Sharp rejections at resistance.

  Sell

• GainSurge

  Dec 4, 2025

  $AVR Unstable price action pointing downward.

  Sell

• ShortSniper

  Dec 4, 2025

  $AVR Breakout above resistance looks imminent.

  Buy

• YieldHunter

  Dec 3, 2025

  $AVR This company is at the forefront of developing innovative medical solutions, showcasing a strong commitment to research and development. Its focus on addressing unmet medical needs positions it as a noteworthy player in the healthcare sector.

  Buy

• ChartNomad

  Dec 3, 2025

  $AVR With groundbreaking technology on the horizon, this stock could skyrocket, but you’ve got to wonder if the hype can actually convert into real profits. Will they deliver, or is it all just talk?

  Buy

• LazyQuant

  Dec 3, 2025

  $AVR More innovative than a cat with a smartphone! If tech were a party, this crew would be the DJ!

  Buy

• AlphaRogue

  Dec 3, 2025

  $AVR This company is like a superhero in the tech world, saving lives and maybe even your next dinner party conversation!

  Buy

• ShortCircuit

  Dec 2, 2025

  $AVR More buzzwords than real innovation. Save your breath.

  Sell

• TradeBlaze

  Dec 2, 2025

  $AVR This organization is at the forefront of medical advancements, focusing on transformative solutions for cardiovascular diseases. As healthcare innovation accelerates, its research-driven approach positions it favorably for long-term success.

  Buy

• FiscalFury

  Dec 2, 2025

  $AVR This company might just be the superhero of your portfolio, ready to swoop in and save the day with some epic gains!

  Buy

• CodeAndCapital

  Dec 1, 2025

  $AVR This company is like a buffet that's all about heart—just makes you feel good inside!

  Buy

• ChartCrusher

  Dec 1, 2025

  $AVR This tech is about as advanced as a flip phone.

  Sell

• TradeTracer

  Dec 1, 2025

  $AVR With a focus on pioneering technologies, this firm is making strides in its industry. Its dedication to innovation and quality positions it well for future growth opportunities.

  Buy

• FOMOKing

  Dec 1, 2025

  $AVR This one's on the rise, ready to take off like a rocket!

  Buy